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The Murine Gammaherpesvirus-68 gp150 Acts as an
Immunogenic Decoy to Limit Virion Neutralization
Laurent Gillet, Janet S. May, Susanna Colaco, Philip G. Stevenson*
Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
Herpesviruses maintain long-term infectivity without marked antigenic variation. They must therefore evade neutralization by
other means. Immune sera block murine gammaherpesvirus-68 (MHV-68) infection of fibroblasts, but fail to block and even
enhance its infection of IgG Fc receptor-bearing cells, suggesting that the antibody response to infection is actually poor at
ablating virion infectivity completely. Here we analyzed this effect further by quantitating the glycoprotein-specific antibody
response of MHV-68 carrier mice. Gp150 was much the commonest glycoprotein target and played a predominant role in
driving Fc receptor-dependent infection: when gp150-specific antibodies were boosted, Fc receptor-dependent infection
increased; and when gp150-specific antibodies were removed, Fc receptor-dependent infection was largely lost. Neither
gp150-specific monoclonal antibodies nor gp150-specific polyclonal sera gave significant virion neutralization. Gp150
therefore acts as an immunogenic decoy, distorting the MHV-68-specific antibody response to promote Fc receptor-dependent
infection and so compromise virion neutralization. This immune evasion mechanism may be common to many non-essential
herpesvirus glycoproteins.
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INTRODUCTION
Antibody is a potent force in anti-viral immunity, neutralizing
virions [1] and promoting infected cell lysis [2]. But while antibody
renders many epidemic viruses non-infectious, it fails to stop the
transmission of persistent viruses. Herpesviruses provide a para-
digm. They both enter and exit immune hosts in the presence of
antibody [3], and moreover show little antigenic variation in so
doing [4], suggesting that antibody even fails to impose much
selective pressure. Poor neutralization within hosts is easy to
understand: herpesviruses spread mainly through cell/cell con-
tacts, which can exclude antibody [5]. Thus, the pseudorabiesvirus
gD, which is required for virion entry, is dispensible for
dissemination in vivo [6], while the Herpes simplex virus gE/gI
complex, which contributes to cell/cell spread, is important [7]. In
this setting, antibody must act mainly through cytotoxicity [8], and
alpha- and beta-herpesvirus consequently encode receptors that
blunt Fc-dependent attack [9,10]. Gamma-herpesviruses do not,
but their host colonization relies more on latency-associated
lymphoproliferation than on lytic replication [11–13].
Poor neutralization of the cell-free virions that transmit infection
between hosts is more difficult to understand. Antibody is clearly
capable of neutralizing mucosal virions in other infections [14].
Also, herpesviruses presumably operate in antibody excess at the
steady state of persistent infection-any antigen excess would simply
elicit more antibody. Alpha-herpesviruses may overwhelm pre-
formed antibody by intermittent, large scale reactivations, and by
replicating in the epidermis where antibody is sparse [15]. But
gammaherpesvirus shed virions fairly constantly and in mucosal
sites where antibody is abundant [16]. Thus, the argument of
quantitative antibody deficiency seems for gamma-herpesviruses to
be unconvincing. However, poor gammaherpesvirus neutraliza-
tion might reflect qualitatively sub-optimal antibody responses.
Despite much functional analysis of whole antibody responses and
many examples of viral glycoprotein-specific monoclonal anti-
bodies (mAbs), there has been little break-down of how well
gammaherpesvirus carriers target each virion glycoprotein. This is
important: fewer than half of the the virion glycoproteins are
essential, and it is far from clear that antibody targets these
selectively. Even an essential glycoprotein will not be a good
neutralization target unless it is immunogenic in natural
infection.
Our understanding of gammaherpesvirus neutralization has
been limited in part by the narrow species tropisms of Epstein-Barr
virus (EBV) and the Kaposi’s Sarcoma-associated Herpesvirus
(KSHV). The major neutralization target defined for EBV-gp350
[17]-is dispensible for epithelial infection [18]. It would anyway
seem unlikely that gp350-specific antibodies could stop EBV
transmission [19]. Neutralization targets apart from gp350 exist
[20], but cognate antibodies may be rare. The difficulties of
analyzing EBV and KSHV directly have made related viruses an
important source of information. One of the most experimentally
accessible is murine gammaherpesvirus-68 (MHV-68), a natural, B
cell-tropic parasite of mice [21–23]. There are limitations on
MHV-68 analysis too-for example, a transmission model has not
yet been developed. Nevertheless, it allows a ready quantitation of
antibody responses and experimental infection with wild-type and
targetted mutant viruses. Immune sera inhibit MHV-68 infection
of fibroblasts [24], probably by blocking cell binding [25]. The
limitations on this mode of neutralization are apparent when
virus/antibody complexes meet IgG Fc receptors: immune sera
then fail to block infection [26], indicating that viral membrane
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response target? The major monoclonal antibody (mAb)-defined
neutralization target is gH/gL [25]. Here we show that the
response mounted against the accessible virion surface is dominat-
ed not by gH/gL-a comparatively minor target-but by the non-
essential gp150. Gp150 was not a significant neutralization target
and instead accounted for much of the capacity of immune sera to
drive IgG Fc receptor-dependent infection. Antibody immuno-
dominance therefore worked against neutralization.
RESULTS
Gp150 dominates immunological footprint of
MHV-68 virions
We aimed to quantitate the antibody response of MHV-68 carriers
to each accessible virion glycoprotein. A key task was to minimize
detection bias. Assays based on recombinant protein expression
potentially allow direct analyses of immune sera. However, each
recombinant protein inevitably varies in how well it reproduces
native virion epitopes. This creates bias. Also, recombinant
proteins may display other epitopes that are accessible on
disrupted virions and therefore immunogenic in vivo, but are
not accessible on intact virions. Another problem with analyzing
immune sera is that non-specific staining can make weak, specific
staining hard to discern. We therefore based our approach on
generating B cell hybridomas from MHV-68-infected mice. We
made use of the fact that MHV-68-infected cells capture virions on
their surfaces [27] and should therefore display all the virion
glycoproteins in their native forms. Thus, we identified antibodies
as potentially (but not necessarily) virion glycoprotein-specific if
they recognized unfixed, MHV-68-infected BHK-21 cells. MAbs
were selected simply for positive staining, without any discrimi-
nation towards stronger or weaker staining. Each was then typed
for its glycoprotein target (Table 1) [28–34]. Although infected
cells may obviously also display non-virion antigens, essentially all
the mAbs that recognized infected cell surfaces were found to
recognize a virion glycoprotein. Using the assays outlined in
Table 1, we consistently identified targets for more than 95% of all
infected cell surface-specific hybrids.
In initial experiments, we infected mice with latency-deficient
MHV-68 [35] to avoid the risk of persistent virus contaminating
the hybridomas. In subsequent experiments with wild-type virus
(Fig. 1A), this was not found to be a significant problem. The
frequencies of glycoprotein-specific mAbs obtained were very
similar. Assuming that splenic B cells are representative of the
whole B cell response and that B cell specificity does not bias
hybrid formation, then splenic hybridoma frequency should reflect
immunogenicity. By this measure, gp150 was much the most
immunogenic virion glycoprotein. It was typically the target of
50% of all infected cell surface-specific mAbs. In one fusion it
reached 69%. In the largest fusion analyzed, 94 (51%) of
184 mAbs recognizing infected cell surfaces recognized gp150.
In the experiment shown (Fig. 1A), all infected cell surface-specific
mAbs recognized either gp150, gp70, gB, gH/gL or gp48. In other
fusions, we also identified mAbs against gN, but we failed to find
any against ORF28 gene products or gM. These are probably
hard for antibody to reach: gM is largely confined to the plane of
the virion membrane, while the ORF28 protein is both small and
heavily glycosylated [33]. ORF58 also encodes a virion compo-
nent (unpublished data), but this associates with and is presumably
protected by the heavily glycosylated gp48 [30]. The immuno-
genic virion surface therefore comprised gp150, gp70, gB, gH/gL,
gp48 and gN. The only mAb-defined MHV-68 neutralization
target apart from gH/gL is gB [36]. Thus, immunodominance did
not correlate with neutralization; if anything, the converse was
true. This was consistent with good neutralizing mAbs being quite
rarely recovered from virus carriers and with the whole response
blocking fusion poorly.
Gp150 immunodominance did not simply reflect abundant
expression. Gp70-specific mAbs stained MHV-68-infected cells
more strongly than gp150-specific mAbs (Fig. 1B), and while
immune sera stained gp70-knockout-infected cells less well than
wild-type, the staining of gp150-knockout-infected cells was the
same (Fig. 1C). Gp70 was therefore more highly expressed than
gp150, implying that gp150 was intrinsically more immunogenic.
A relatively small region of gp150 accounts for
much of its immunogenicity
The 460 amino acid extracellular domain of gp150 is predicted to
be strongly anionic with.100 O-linked glycosylation sites. Dis-
counting the predicted signal peptide (residues1–22) and a small
N-terminal domain (residues23–93), 94% of its amino acids are A,
D, E, P, S or T. The bulk of gp150 is therefore likely to form an
extended, hydrophilic stalk stabilized by O-linked glycans. It
readily binds to the O-glycan-specific lectin jacalin [33]. We
identified particularly immunogenic regions of gp150 by ELISA of
protein fragments fused to GST (Fig. 2A, 2B). MAbs were first
tested against the entire gp150 extracellular domain in 3 segments:
residues 21–151, 108–269 and 269–461 (Fig. 2C). These results
were confirmed by testing reactivity against cells transfected with
either full-length gp150 or a truncated form comprising its first
151 residues plus a glycosyl-phosphatidylinositol membrane
anchor (Fig. 2D). Most mAbs recognized the region up to residue
151. We mapped recognition more finely within residues 21–151
using a series of N-terminal truncation mutants (Fig. 2E). No mAbs
recognized residues 21–41 and few recognized 42–107. A relatively
small region of the gp150 stalk-residues 108–151-accounted for
half of all the gp150-specific mAbs we derived (Fig. 2F). Over-
lapping 15-mer peptides covering this region (Fig. 2G) reproduced
the cognate epitope of 11/44 mAbs. Thus, the most immunogenic
part of gp150 appeared to have a predominantly linear structure.
20/20 gp150-specific mAbs specific for residues 108–269 recog-
nized denatured antigen on immunoblots (data not shown),
consistent with the most immunogenic part of the native protein
forming linear epitopes.
Gp150-specific mAbs drive IgG Fc
receptor-dependent infection
The immunodominance of gp150 as an antibody target suggested
that gp150-specific antibodies might influence significantly the fate
Table 1. Identification of MHV-68 glycoprotein-specific mAbs.
......................................................................
Protein Primary identification Secondary identification
gB [28] transfected cell line 120kDa IP product
gH/gL [25] 85kDa IP product transfected cell line
gp48 [29] knockout virus transfected cell line
ORF58 [30] knockout virus transfected cell line
gp70 [31] transfected cell line knockout virus
ORF74 [32] knockout virus transfected cell line
gp150 [27] knockout virus transfected cell line
ORF28 [33] knockout virus transfected cell line
gN/gM [34] transfected cell line 35kDa IP product
doi:10.1371/journal.pone.0000705.t001
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of immune sera on MHV-68 virions: an inhibition of IgG Fc
receptor (FcR)-independent infection [24,37], and an enhance-
ment of FcR-dependent infection [26]. We therefore tested 115
gp150-specific mAbs for their effect on MHV-68 infection of
FcR
2 and FcR
+ cells, using human cytomegalovirus IE-1
promoter-driven eGFP expression as a readout of infection. This
tends to underestimate the total level of infection within a given
cell population, but provides a reliable, validated comparison of
infection levels between populations [26]. None of the mAbs
reduced the infection of BHK-21 cells (FccR
2) or NS0 myeloma
cells (FccRII
+), regardless of whether exogenous mouse comple-
ment was present or not (data not shown). All enhanced the
infection of RAW264.7 cells (FccRI
+ FccRIII
+), some to very high
levels (Fig. 3A). Gp150-specific mAbs therefore increased virion
infectivity (Fig. 3B).
The gp150 positional homolog in EBV-gp350-inhibits EBV
infection of epithelial cells [38]. This inhibition can be partly offset
by gp350-specific mAbs [39]. Gp150 mediates an analogous
inhibition of GAG-deficient cell infection by MHV-68 [27] and
gp150-specific mAbs were able to increase MHV-68 infection of
GAG-deficient CHO cells (Fig. 3C). However, the enhancement
was less marked than for FcR
+ cells and required more antibody.
Also, immune sera contained insufficient gp150-specific antibody
relative to infection blocking antibody to enhance GAG-deficient
CHO cell infection (Fig. 3C), whereas immune sera do enhance
RAW264.7 cell infection [26]. Thus, at least for MHV-68, FcR-
independent infection enhancement by gp150-specific antibodies
is probably not of great practical importance.
Most serum-mediated, FcR-dependent infection is
due to gp150
The potency of gp150-specific mAbs in driving FcR-dependent
infection suggested that gp150 might be responsible for much of
this effect of immune sera. We determined the contribution of
gp150 by comparing sera from mice 2 months after infection with
either wild-type or gp150-deficient viruses (Fig. 4A). Gp150
knockout-immune sera gave much less enhancement than wild-
type. Similar results were obtained at 6 months post-infection
(Fig. 4B). Absorbing gp150-specific antibodies out of wild-type-
immune serum also largely abolished its infection enhancing effect
(Fig. 4C).
Removing gp150-specific antibodies from immune sera had no
effect on the neutralization of BHK-21 cell infection (data not
shown) and pooled gp150 knockout-immune sera neutralized wild-
type MHV-68 for BHK-21 cell infection somewhat better than
pooled wild-type-immune sera did (Fig. 5A), consistent with gp150
not being a significant neutralization target. More variable but
essentially similar results were obtained with individual sera
(Fig. 5B). Frequency analysis of glycoprotein-specific hybridomas
(n.150) from gp150 knockout virus carriers showed that, except
for gp150, the basic immunodominance hierarchy was main-
tained. The percentages of mAbs specific for each glycoprotein
were: gp150-0%, gp70-45%, gB-24%, gH/gL-23%, ORF27-7%,
gM/gN-2%. Thus, a lack of gp150 not only had no adverse effect
on neutralization, but also allowed greater stimulation of other,
potentially neutralizing B cells.
Boosting gp150-specific immunity boosts IgG Fc
receptor-dependent infection
We also tested whether gp150 mono-specific immune sera could
boost FcR-dependent infection. To do this, we generated
a vaccinia virus recombinant expressing amino acid residues 1–
151 (the most immunogenic region) of gp150 with a GPI anchor
(VAC-150) (Fig. 6A). VAC-150 elicited an antibody response from
naive mice that increased FcR-dependent MHV-68 infection,
whereas a control vaccinia virus recombinant did not (Fig. 6B).
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Figure 1. Gp150 is the most immunogenic MHV-68 glycoprotein. A.
Hybridomas were derived from the pooled spleens of 3 BALB/c mice
5 months after intranasal MHV-68 infection. Each mAb that recognized
unfixed, MHV-68-infected BHK-21 cells was typed for its glycoprotein
target as outlined in Table 1. None remained unaccounted for. The data
shown are from 1 fusion experiment that generated 128 glycoprotein-
specific mAbs. 5 further experiments all gave similar results. B. BHK-21
cells were either uninfected (UI, solid lines) or infected with wild-type
MHV-68 (2 PFU/cell, 18h: vir, dashed lines) and stained with mAbs specific
for gp70 orgp150.Histograms for 3 mAbs,allusedinsaturatingamounts,
are overlaid in each graph. Gp70-specific staining was consistently
strongerthan thatofotherviral glycoproteins,includinggp150.C.BHK-21
cells were either uninfected (UI, solid lines) or infected (2 PFU/cell, 18h)
with wild-type (WT, dashed lines), gp150-deficient (gp150 KO, dotted
lines)orgp70-deficient(gp70KO,dottedlines)viruses.Thecellswerethen
stained with sera from mice infected with wild-type, gp150-deficient or
gp70-deficient viruses, or from age-matched naive mice.
doi:10.1371/journal.pone.0000705.g001
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Figure 2. Epitope mapping for gp150-specific mAbs. A. Gp150 comprises an N-terminal signal sequence, a small N-terminal domain, a long stalk rich
in anionic residues, proline residues and potential O-glycosylation sites (A/D/E/P/T/S-rich domain), a transmembrane domain and a short cytoplasmic
tail. Our analysis focussed on the membrane-distal half of the protein. B. GST fusion proteins were purified with glutathione-sepharose, separated by
SDS-PAGE and Coomassie stained. Longer regions of the stalk domain were less well expressed than shorter forms and were subject to more
degradation. C. MAb recognition was mapped by ELISA with GST fusion proteins covering the gp150 extracellular domain. Examples of fusion protein
recognition are shown (mAbs T1A1, T4G2 and 150-41, with their deduced recognition sites given below). Despite the limited amino acid diversity of
gp150, little mAb cross-reactivity was evident between the expressed protein segments. The gH/gL-specific mAb T4C5 provided a negative control.
D. Recognition patterns were confirmed by flow cytometric staining of 293T cells transfected with either full-length gp150 or the N-terminal 151
residues of gp150 with a GPI membrane anchor. Examples of staining are shown. Control=secondary antibody only. E. More detailed analysis of the
N21-C151 region, which accounted for most gp150-specific mAbs, using N-terminal gp150 truncations. Virus=wells coated with 0.01% Triton X-100-
disrupted MHV-68 virions, GST=GST alone. Examples of recognition patterns are shown. The gp70-specific mAb 6H10 provided a negative control for
gp150 recognition. F. Summary of GST fusion protein recognition by 81 gp150-specific mAbs. G. MAb specificities within the 108-151 region were
mapped with overlapping 15-mer biotinylated peptides bound to avidin-coated plates. The amino acid residues covered by each peptide are
indicated. Examples of recognition patterns are shown with the total number of mAbs showing that pattern.
doi:10.1371/journal.pone.0000705.g002
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+ T cell response to MHV-68 can be
changed by post-exposure vaccination [40]. To test whether the
antibody response could be changed in the same way, we super-
infected MHV-68 carrier mice with VAC-150. This boosted
serum antibody titers to gp150 residues 1–151 without a change in
titers to residues 269–461 (Fig. 6C). The boosted sera gave more
FcR-dependent infection (Fig. 6D). Immunization with VAC-150
did not, by contrast, affect the neutralization titers of either naive
or MHV-68 carrier mice (Fig. 6E). These data confirmed that the
gp150-specific component of the antibody response mediates Fc
receptor-dependent infection rather than neutralization, and is
therefore likely to benefit the virus rather than the host.
DISCUSSION
Antibody can attenuate herpesvirus-induced disease, but neither
prevents viral transmission nor drives obvious viral antigenic
variation. Immune sera stop MHV-68 virions binding to
fibroblasts. However, they promote FcR-dependent infection
[26], suggesting that viral membrane fusion remains intact. Thus,
so long as an alternative uptake route is available, antibody-
exposed virions remain infectious. Here we analysed the antibody
response to the accessible MHV-68 virion surface, in order to
establish an immunological basis for FcR-dependent infection.
The immunodominant virion antibody target was gp150. Gp150-
specific antibodies did not neutralize. Instead, they played the
major role in whole sera of driving FcR-dependent infection. The
gp150-specific response also suppressed somewhat the neutralizing
antibody response. In contrast to gp150, the major mAb-defined
MHV-68 neutralization target, gH/gL, was poorly immunogenic.
Thus gp150, though its immunogenicity, distorts the antibody
response and reduces its impact on virion infectivity. Many
complex pathogens could compromise antibody responses with
non-essential glycoproteins in the same way.
The most immunogenic region of gp150 lay in its serine/
threonine-rich stalk. This appeared to have a linear structure, in
that most mAbs recognizing the native protein also recognized
denatured forms. The preservation of gp150 epitopes in protein
fragments may explain its immunodominance, as infected cell
21-107 270-461 / untyped 152-269 108-151
0
25
50
75
100
%
 
e
G
F
P
+
 
c
e
l
l
s
virus pre-treated with anti-gp150
B
A
uninfected
virus only
mAb T7F5 mAb T1A1 immune serum
CHO GAG+ virus +Ab
CHO GAG- virus + Ab
CHO GAG+ virus only
CHO GAG- virus only
0
25
50
75
100 05 0 1 0 0 05 0 1 0 0 05 0
%
 
e
G
F
P
+
 
c
e
l
l
s
antibody concentration (%)
C
20
10
0
antibody [µg/ml]
50
40
30
10 20 30 40 0
RAW (MOI=5)
BHK (MOI=0.3)
%
 
e
G
F
P
+
 
c
e
l
l
s
mAb T4G2
Figure 3. Effect of gp150-specific mAbs on MHV-68 virion infectivity. A. EGFP-expressing MHV-68 virions were incubated with hybridoma
supernatants (1 h, 37uC) and then added to RAW264.7 macrophages (3 PFU/cell). 18h later, the number of infected cells was determined by flow
cytometric assay of viral eGFP expression. The mAbs are grouped by the region of gp150 recognized. The bars indicate the %eGFP
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-) MHV-68. Gp150-specific antibodies were removed from wild-type-immune sera by 3 rounds of incubation on 2%
paraformaldehyde-fixed CHO-gp150 cells (see Figure 2D) (WT abs-150). Controls were incubated on paraformaldehyde-fixed CHO cells (WT abs-C).
Wild-type or gp150-deficient viruses were incubated with each serum sample and then used to infected RAW264.7 cells (3 PFU/cell, 18 h). The data
are representative of 2 experiments.
doi:10.1371/journal.pone.0000705.g004
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stimulate gp150-specific B cells. In contrast, neutralizing epitopes
on gH/gL are lost when these proteins dissociate [25,41]. The
simple, predominantly hydrophilic amino acid composition of
gp150 could also be important in allowing a range of strong,
electrostatic antibody interactions. Despite the diversity of gp150
homologs in different gammaherpesvirus, a serine/threonine rich
domain is conserved. The EBV and KSHV homologs-gp350 and
K8.1-also appear to be strongly immunogenic [17,42]. Thus,
gp150 immunogenicity could represent a general gammaherpes-
virus strategy of antibody subversion. Deliberate immunogenicity
might seem counter-productive for EBV, since gp350 contributes
to B cell infection [43], but in vivo B cell infection may not require
cell-free EBV. Direct spread from epithelial cells is also possible.
Gp150 may be specifically adapted to non-standard infection
routes. For example, its A/D/E/P/S/T-rich stalk could be
sufficiently mobile to accomodate bulky antibodies and still allow
membrane apposition for fusion. However, gp150 knockout-
immune sera still gave some enhancement of RAW264.7 cell
infection (Fig. 4A), as do mAbs specific for other glycoproteins
[26], so this effect of gp150 was not unique. Nor, presumably, was
its suppression of neutralizing specificities: gp70, second in
immunodominance and again non-essential, should have a similar
effect. Thus, while gp150 provides a striking example of how
immunodominance works against neutralization, other non-
essential glycoproteins could have similar effects. How would
immunodominance work? Germinal centre B cells must take up
and present antigen to survive [44]. Herpesviruses glycoproteins
often associate and they all come together in virions. B cells
endocytosing one glycoprotein will therefore tend to endocytose
others too, much as influenza hemagglutinin-specific B cells also
take up non-hemagglutinin antigens [45]. Germinal B cells
recognizing different herpesvirus glycoproteins should therefore
compete for antigen via their requirement for T cell help, allowing
non-neutralizing B cells to suppress neutralizing responses.
Notably, the total glycoprotein-specific antibody responses to
wild-type and gp150-deficient MHV-68 were very similar (Fig. 1C):
when the gp150-specific response was lost, that to other targets
increased.
Stewart et al. have argued that gp150 is important for B cell
infection [46]. We find no evidence for this. Indeed, gp150-
deficient MHV-68 binds to and infects GAG-deficient cells much
better than wild-type, not worse [27,31]. Our data are consistent
instead with the glycosaminoglycan binding reported for the
gp150 homologs of other gamma-2-herpesviruses [47–49]. Gp150
binding to glycosaminoglycans, though weak [31], is still
functionally important [27]. Our data suggest that gp150 works
not by providing strong binding, but by providing glycosamino-
glycan-sensitive regulation of cell binding by another virion
glycoprotein, possibly gB [27,31].
Gp150 mutants show normal host colonization [27]. However,
this reflects not that gp150 is unimportant, but that the current
MHV-68 pathogenesis model measures mainly primary infection
and disease. At least the former is not where gp150 acts. Many
MHV-68 lytic genes will contribute to disease, as MHV-68 causes
disease mainly by lytic replication [51,52]. In contrast, EBV and
KSHV cause disease mainly when latent. The value of MHV-68
as a specific disease model is therefore debatable, and we have not
pursued it. MHV-68 would seem to be a much better model for
normal gamma-herpesvirus infection. Primary host colonization
by MHV-68 depends more on latency-associated lymphoprolifera-
tion than on lytic replication [11–13], so here lytic genes that have
been conserved over millions of years often have rather minor
pathogenesis phenotypes [27,29,33,50]. Defining their true in vivo
importance requires a better pathogenesis model. The two known
functions of gp150-virion release [27] and antibody evasion-would
be consistent with an important role in transmission. MHV-68,
like murine cytomegalovirus, is poorly transmitted between
conventionally housed mice. Our goal now is therefore to establish
experimental transmission by reproducing more accurately the
natural social interactions of the infected host.
MATERIALS AND METHODS
Mice and monoclonal antibodies
BALB/c and C57BL/6J mice were purchased from Harlan U.K.
Ltd. (Bicester, U.K.), housed in the Cambridge University
Department of Pathology and infected intranasally with 3610
5
PFU MHV-68 when 6–8 weeks old (Home Office Project Licence
80/1579). Vaccinia viruses were given by intraperitoneal injection
(3610
6 PFU). For mAb production, mice were boosted with 10
7
PFU intraperitoneal MHV-68 3–6 months after intranasal in-
fection when both the viral load and serum antibody have reached
steady state [24,37]. Splenocytes were harvested 3 days later and
fused with NS0 cells using polyethylene glycol 1500 [53]. Cell
hybrids were grown on monolayers of irradiated MRC-5 cells in
20% FCS and selected with azaserine (1 mg/ml)/hypoxanthine
(100 mM). MAbs were concentrated from tissue culture superna-
tant by ammonium sulfate precipitation and quantitated by ELISA
using isotype-matched standards.
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Figure 5. The antibody response to gp150 tends to reduce rather
than enhance MHV-68 neutralization. A. Wild-type MHV-68 virions
(1000 PFU/sample) were incubated with sera pooled from 5 mice
2 months after infection with gp150
+ (WT, REV) or gp150
2 (M7
-FRT,
M7
-STOP) viruses and then used to infect BHK-21 cells. Control samples
were BHK-21 cells infected with virus and no antibody. B. Sera from
C57BL/6 mice 3 months after infection with wild-type (WT) or M7
-STOP
(gp150
2) MHV-68 was used to inhibit wild-type MHV-68 infection of
BHK-21 cells. Despite variation between individual mice, plaque titers
were significantly lower with the 2% and 6% sera from gp150 knockout-
infected mice (p,0.01 by Student’s t test).
doi:10.1371/journal.pone.0000705.g005
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The gp150 coding sequence (genomic co-ordinates 69466-70917)
[54] was amplified by PCR (Hi-Fidelity PCR kit, Roche
Diagnostics Ltd), using 5’ EcoRI-restricted and 39 XhoI-restricted
primers, and cloned into the EcoRI/XhoI sites of pMSCV-IRES-
ZEO [55]. This plasmid was used for retroviral transduction [55]
of L929 cells to make a cell line stably expressing gp150. The
coding sequence for amino acid residues 1–151 was amplified with
59 XbaI-restricted and 39 NotI-restricted primers and cloned into
the XbaI/NotI sites of pBRAD, thereby attaching a C-terminal
glycosyl-phosphatidyl-inositol (GPI) membrane anchor [28]. To
fuse gp150 fragments to N-terminal GST, the relevant portions of its
coding sequence were amplified by PCR with 59 EcoRI-restricted
and 39 XhoI-restricted primers and cloned into the EcoRI/XhoIs i t e s
of pGEX-4T-1 (APBiotech, Little Chalfont, U.K.). Expression in
BL-21E.coli.wasinducedfor4hwith400 mMIPTG.TheE.coliwere
lysed in 1% Triton X-100/50 mM TrisCl pH 7.4/150 mM NaCl/
5mM EDTA/1mM PMSF/5mM N-ethyl-maleimide/Complete
protease inhibitors (Roche Diagnostics). GST fusion proteins were
precipitated with glutathione-sepharose beads (APBiotech), washed
63 in lysis buffer and 62 in Tris-saline, eluted with 50mM
glutathione and dialysed 63 against PBS.
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Figure 6.Boosting gp150-specific immunity in carrier mice increases FcR-dependent infection and has no effect on neutralization. A. BHK-21
cells were left uninfected (solid lines) or infected (2PFU/cell 18h) with MHV-68 (dashed lines) or VAC-150 (dotted lines), then assayed for cell surface
gp150 expression by flow cytometry. MAb T4G2 recognizes an epitope in gp150 amino acid residues 108–151. MAb T1A1 recognizes an epitope in
amino acid residues 152–269. VAC-150 expresses residues 1–151 with a GPI anchor. B. BALB/c (BC) or C57BL/6J (B6) mice were either left uninfected
or infected with VAC-gp150. At the times post-infection indicated, sera were incubated with eGFP-expressing MHV-68. The serum/virus mixtures were
then used to infect RAW264.7 macrophages. Infection was quantitated 18h later by flow cytometric assay of viral eGFP expression. The data are from
1 of 2 equivalent experiments. C. C57BL/6 mice were infected intranasally with MHV-68. 3 months later they were boosted with VAC-150 (+VAC-150)
or a control vaccinia virus expressing the Herpes simplex virus gE (+VAC-gE) or left unboosted (MHV-68). Naive=age-matched, uninfected mice.
Immune sera were pooled from groups of 3 mice. A and B are separate pools for each treatment arm. The sera were assayed by ELISA for reactivity
against N-terminal (residues 21–151) or C-terminal (residues 269–461) fragments of gp150. Only the N-terminal part is expressed by VAC-150. D. The
same sera as in C were added to eGFP
+ MHV-68 virions and the mixtures added to RAW264.7 cells. 18h later, eGFP expression was quantitated by flow
cytometry. The data are from 1 of 3 equivalent experiments. E. C57BL/6 and BALB/c mice were either left uninfected (naive), infected with MHV-68 or
VAC-gp150, or infected with MHV-68 and then boosted with VAC-gp150. Pooled sera from these mice (5 per group) were then tested for MHV-68
neutralization by plaque assay. Infection with VAC-gp150 made no detectable difference to neutralization titers. The data are from 1 of 2 equivalent
experiments.
doi:10.1371/journal.pone.0000705.g006
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All cells were grown in Dulbecco’s modified Eagle medium
(Invitrogen, Paisley, U.K.) supplemented with 2mM glutamine,
100U/ml penicillin, 100 mg/ml streptomycin and 10% fetal calf
serum (PAA laboratories, Linz, Austria). Where indicated, cells were
transfected using Fugene-6 (Roche Diagnostics Ltd., Lewes, U.K.).
Viruses
MHV-68 was derived from a genomic BAC, which also transcribes
eGFP from a human cytomegalovirus IE-1 promoter [56]. For all in
vivo experiments, the loxP flanked eGFP and BAC sequences were
removed by passaging viruses through NIH-3T3-CRE cells [57].
Two, non-overlapping gp150-deficient mutants, M7
-FRT and
M7
-STOP, and a revertant of the M7
-FRT mutant have been
described [27]. Viruses were grown in BHK-21 cells. Infected
cultures were cleared of infected cell debris by low-speed centri-
fugation (10006g, 3min). Virions were then concentrated by high
speed centrifugation(380006g,90min).Virustitersweredetermined
by plaque assay on BHK-21 cells [27]. To make VAC-gp150, the
GPI-linked coding sequence for amino acid residues 1–151 was
subcloned from pBRAD into pMJ601 [58] and then transfected into
vaccinia virus WR-infected TK
-143 cells. Thymidine kinase-
deficient recombinants were selected by passage in TK
-143 cells
with 25 mg/ml 59-bromo-29-deoxyuridine (Sigma Chemical Co,
Poole, U.K.) and identified by beta galactosidase assay with X-gal.
They were purified to homogeneity by limiting dilution cloning.
Flow cytometry
Cells infected with eGFP
+ viruses were washed in PBS and
analysed directly for green channel fluorescence. For specific
staining, cells were incubated with MHV-68 glycoprotein-specific
mAbs (1 h, 4uC), washed 62 in PBS, incubated with fluorescein-
conjugated rabbit anti-mouse IgG pAb (Dako Cytomation, Ely,
U.K.), washed 62, and analysed on a FACS Calibur (Becton-
Dickinson, Oxford, U.K.). Graphs were plotted with FCSPress
v1.3 (www.fcspress.com).
ELISA
Nunc Maxisorp ELISA plates (Nalge Nunc, N.Y.) were coated
(18 h, 4uC) with GST fusion proteins, blocked in PBS/0.1%
Tween-20/1% BSA, and incubated with hybridoma supernatant.
Bound antibody was detected with horseradish peroxidase-
conjugated goat anti-mouse IgG pAb (Sigma). For fine mapping,
instead of GST fusion proteins, biotinylated 15-mer peptides
(Peptide Therapeutics, Eastleigh, U.K.) were captured onto
ELISA plates pre-coated with 10 mg/ml avidin (Sigma). For total
MHV-68 recognition, the plates were coated with 0.01% Triton
X-100-disrupted MHV-68 virions. The plates were washed 65i n
PBS/0.1% Tween-20 after each step. The detection substrate was
nitrophenylphosphatate (Sigma). Absorbance was read at 405nm
using a Benchmark ELISA plate reader (BioRad, Hercules, CA).
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